100 related articles for article (PubMed ID: 20545952)
1. T-cell clone associated with efalizumab therapy.
Lynch M; Murphy K; Slaby J; Kirby B
Clin Exp Dermatol; 2011 Jan; 36(1):99-100. PubMed ID: 20545952
[No Abstract] [Full Text] [Related]
2. A case of natural killer cell monoclonal expansion during efalizumab treatment in a patient with psoriasis.
Caproni M; Volpi W; Chiarini C; Antiga E; Giomi B; Fabbri P
Br J Dermatol; 2009 Apr; 160(4):896-7. PubMed ID: 19239461
[No Abstract] [Full Text] [Related]
3. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy.
Berthelot C; Cather J; Jones D; Duvic M
Clin Lymphoma Myeloma; 2006 Jan; 6(4):329-32. PubMed ID: 16507211
[TBL] [Abstract][Full Text] [Related]
4. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
[TBL] [Abstract][Full Text] [Related]
5. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
[TBL] [Abstract][Full Text] [Related]
6. Efalizumab-induced guttate psoriasis. Successful management and re-treatment.
Balato A; La Bella S; Gaudiello F; Balato N
J Dermatolog Treat; 2008; 19(3):182-4. PubMed ID: 18569275
[TBL] [Abstract][Full Text] [Related]
7. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.
Vugmeyster Y; Kikuchi T; Lowes MA; Chamian F; Kagen M; Gilleaudeau P; Lee E; Howell K; Bodary S; Dummer W; Krueger JG
Clin Immunol; 2004 Oct; 113(1):38-46. PubMed ID: 15380528
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
9. Efalizumab-induced thrombocytopenia: report of relapse after re-administration.
Kiorpelidou D; Tsiouri G; Gaitanis G; Akritidis N; Bassukas ID
Clin Exp Dermatol; 2009 Dec; 34(8):e914-6. PubMed ID: 20055866
[TBL] [Abstract][Full Text] [Related]
10. Development of monoclonal gammopathy in 12 patients receiving efalizumab treatment for chronic plaque psoriasis.
Prignano F; Pescitelli L; Ricceri F; Ermini A; Lotti T
J Am Acad Dermatol; 2010 Oct; 63(4):e84-7. PubMed ID: 20846561
[No Abstract] [Full Text] [Related]
11. Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies.
van Lingen RG; Körver JE; van de Kerkhof PC; Berends MA; van Rens DW; Langewouters AM; Boezeman JB; Seyger MM; de Jong EM
Br J Dermatol; 2008 Jul; 159(1):91-6. PubMed ID: 18476954
[TBL] [Abstract][Full Text] [Related]
12. Molecular and flow cytometry characterization during the follow-up of three simultaneous lymphoproliferative disorders: hairy cell leukemia, monoclonal B-cell lymphocytosis, and CD4(++) /CD8(+/- dim) T-large granular lymphocytosis--a case report.
Garrido P; Jiménez P; Sánchez C; Valero F; Balanzategui A; Almagro M; López P; de Pablos JM; Navarro P; Cabrera A; González M; Jurado M; Ruiz-Cabello F
Cytometry B Clin Cytom; 2011 May; 80(3):195-200. PubMed ID: 21520406
[TBL] [Abstract][Full Text] [Related]
13. Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment.
Kop EN; Körver JE; Van Ruysevelt D; De Jong EM; Van der Valk PG; Van de Kerkhof PC
J Dermatolog Treat; 2009; 20(1):67-9. PubMed ID: 18651300
[TBL] [Abstract][Full Text] [Related]
14. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
[TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study.
Tsai TF; Liu MT; Liao YH; Licu D
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):345-52. PubMed ID: 18005021
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis.
Toth DP; Papp K; Gratton D
Dermatol Ther; 2008; 21 Suppl 3():S6-14. PubMed ID: 19076630
[TBL] [Abstract][Full Text] [Related]
17. Efalizumab-associated Guillain-Barre syndrome.
Victor F; Menon K; Latkowski JA; Fernandez-Obregon A; Strober BE
Arch Dermatol; 2008 Oct; 144(10):1396-7. PubMed ID: 18936412
[No Abstract] [Full Text] [Related]
18. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.
Bonnekoh B; Pommer AJ; Böckelmann R; Hofmeister H; Philipsen L; Gollnick H
Skin Pharmacol Physiol; 2007; 20(5):237-52. PubMed ID: 17587888
[TBL] [Abstract][Full Text] [Related]
19. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Gottlieb AB; Gordon KB; Lebwohl MG; Caro I; Walicke PA; Li N; Leonardi CL;
J Drugs Dermatol; 2004; 3(6):614-24. PubMed ID: 15624744
[TBL] [Abstract][Full Text] [Related]
20. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
